Current Research in Translational Medicine最新文献

筛选
英文 中文
Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH) 细胞遗传学在骨髓增殖性肿瘤、肥大细胞增多症和骨髓增生异常/骨髓增殖性肿瘤治疗中的应用:来自法语细胞组织(GFCH)的指南
IF 4.1 4区 医学
Current Research in Translational Medicine Pub Date : 2023-10-01 DOI: 10.1016/j.retram.2023.103424
Matthieu Decamp , Emilie Klein , Catherine Godon , Valentin Lestringant , Pauline Roynard , Olivier Theisen , Mélanie Jimenez-Pocquet , Catherine Roche-Lestienne , Audrey Bidet , Lauren Veronese
{"title":"Cytogenetics in the management of myeloproliferative neoplasms, mastocytosis and myelodysplastic/myeloproliferative neoplasms: Guidelines from the Group Francophone de Cytogénétique Hématologique (GFCH)","authors":"Matthieu Decamp ,&nbsp;Emilie Klein ,&nbsp;Catherine Godon ,&nbsp;Valentin Lestringant ,&nbsp;Pauline Roynard ,&nbsp;Olivier Theisen ,&nbsp;Mélanie Jimenez-Pocquet ,&nbsp;Catherine Roche-Lestienne ,&nbsp;Audrey Bidet ,&nbsp;Lauren Veronese","doi":"10.1016/j.retram.2023.103424","DOIUrl":"10.1016/j.retram.2023.103424","url":null,"abstract":"<div><p>Myeloproliferative neoplasms, mastocytosis, myeloid/lymphoid neoplasms with hypereosinophilia and tyrosine kinase gene fusions, and myelodysplastic/myeloproliferative neoplasms are clonal hematopoietic cancers that, with the exception of certain entities, have an indolent course.</p><p>In addition to their increasingly important role in the diagnosis of these entities, as shown by the recent classification of hematolymphoid tumors in the 5th edition of the World Health Organization and the International Consensus Classification of myeloid neoplasms and acute leukemias, identification of the profile of acquired genetic abnormalities is essential for adapting patient management and early detection of patients at high risk of progression.</p><p>Alongside molecular abnormalities, cytogenetic abnormalities play an important role in the diagnosis, prognosis and follow-up of these diseases.</p><p>Here, we review the recent literature on the impact of chromosomal abnormalities in these different entities and provide updated cytogenetic recommendations and guidelines for their management.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 4","pages":"Article 103424"},"PeriodicalIF":4.1,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135965590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Normal and Mutated APOL1 G2 Rs60910145 alleles with SCD, Body Mass Index, and Renal Function Biomarkers and Indices 正常和变异 APOL1 G2 Rs60910145 等位基因与 SCD、体重指数和肾功能生物标志物及指标的关系
IF 4.1 4区 医学
Current Research in Translational Medicine Pub Date : 2023-09-29 DOI: 10.1016/j.retram.2023.103414
Abazar Mahmoud Ismail , Bakri Mohammed Nour , Adam Dawoud Abakar , Babiker Saad Almugadam , Hisham N. Altayb , Rania TagEsir Ahmed , Mubarak Elsaeed Mustafa Elkarsany
{"title":"Association of Normal and Mutated APOL1 G2 Rs60910145 alleles with SCD, Body Mass Index, and Renal Function Biomarkers and Indices","authors":"Abazar Mahmoud Ismail ,&nbsp;Bakri Mohammed Nour ,&nbsp;Adam Dawoud Abakar ,&nbsp;Babiker Saad Almugadam ,&nbsp;Hisham N. Altayb ,&nbsp;Rania TagEsir Ahmed ,&nbsp;Mubarak Elsaeed Mustafa Elkarsany","doi":"10.1016/j.retram.2023.103414","DOIUrl":"10.1016/j.retram.2023.103414","url":null,"abstract":"<div><h3>Purpose of the study</h3><p>: The current study aimed to detect the frequency of normal and mutated APOL1<span><span> alleles in sickle cell disease (SCD) patients and test their relation with </span>Microalbuminuria<span><span>, Creatinine, Urea, Glomerular Filtration Rate (GFR), and </span>Body Mass Index (BMI).</span></span></p></div><div><h3>Patients and Methods</h3><p>: The study included 156 SCD subjects. Serum Creatinine<span> (mg/dl) and Urea (mg/dl) as well as Microalbuminuria (mg/l) level were measured by using Biosystems kit (Biosystems, Barcelona, Spain) and Mindary BA88A semi-automated biochemistry analyzer. Glomerular filtration rate and body mass index were calculated by equations. Blood DNA extraction was achieved by using the modified G-DEX™IIb Genomic DNA Extraction Kit protocol. The PCR was done for the detection of the APOL1 G2 rs60910145 alleles by using allele-specific PCR and primers.</span></p></div><div><h3>Results</h3><p>: The CC allele was more frequent in study cases (66.7%) than TT allele. The frequency of a mutated allele (CC) was insignificantly higher in males (67.8%) than in females (65.2%) and in rural (70.9%) than urban areas. It is also higher in Shankhab compared to other tribes and subjects 26-37 years compared to other, P˃0.05. Interstingly, the subjects who carry the CC allele showed a significantly higher level of Microalbuminuria, Creatinine, BMI, and Urea compared to those carry TT allele. Moreover, GFR is also higher in subjects who carry CC than TT allele but it is not significant.</p></div><div><h3>Conculsion</h3><p>: Altogether, the study findings highlighted the link of normal and mutated APOL1 G2 rs60910145 alleles with SCD and displayed the significant value of mutated APOL1 allele in the prediction of early nephropathy in SCD patients.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 1","pages":"Article 103414"},"PeriodicalIF":4.1,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135588236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biochemical pancreatic β-cell lineage reprogramming: Various cell fate shifts 生化胰腺β细胞系重编程:各种细胞命运转变
IF 4.1 4区 医学
Current Research in Translational Medicine Pub Date : 2023-09-21 DOI: 10.1016/j.retram.2023.103412
Yuqin Wang , Zhuoqing Liu , Shengren Li , Xuejuan Su , Keng Po Lai , Rong Li
{"title":"Biochemical pancreatic β-cell lineage reprogramming: Various cell fate shifts","authors":"Yuqin Wang ,&nbsp;Zhuoqing Liu ,&nbsp;Shengren Li ,&nbsp;Xuejuan Su ,&nbsp;Keng Po Lai ,&nbsp;Rong Li","doi":"10.1016/j.retram.2023.103412","DOIUrl":"10.1016/j.retram.2023.103412","url":null,"abstract":"<div><p><span><span><span>The incidence of pancreatic diseases has been continuously rising in recent years. Thus, research on pancreatic regeneration is becoming more popular. Chronic </span>hyperglycemia<span> is detrimental to pancreatic β-cells, leading to impairment of insulin secretion which is the main hallmark of pancreatic diseases. Obtaining plenty of functional pancreatic β-cells is the most crucial aspect when studying pancreatic biology and treating diabetes. According to the International Diabetes Federation, diabetes has become a global epidemic, with about 3 million people suffering from diabetes worldwide. Hyperglycemia can lead to many dangerous diseases, including amputation, </span></span>blindness, </span>neuropathy<span>, stroke, and cardiovascular and kidney diseases<span>. Insulin is widely used in the treatment of diabetes; however, innovative approaches are needed in the academic and preclinical stages. A new approach aims at synthesizing patient-specific functional pancreatic β-cells. The present article focuses on how cells from different tissues can be transformed into pancreatic β-cells.</span></span></p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 1","pages":"Article 103412"},"PeriodicalIF":4.1,"publicationDate":"2023-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135388928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring clues pointing toward the existence of a brain-gut microbiota-hair follicle axis 探索大脑-肠道微生物群-毛囊轴存在的线索
IF 4.1 4区 医学
Current Research in Translational Medicine Pub Date : 2023-09-10 DOI: 10.1016/j.retram.2023.103408
Yang Feng
{"title":"Exploring clues pointing toward the existence of a brain-gut microbiota-hair follicle axis","authors":"Yang Feng","doi":"10.1016/j.retram.2023.103408","DOIUrl":"10.1016/j.retram.2023.103408","url":null,"abstract":"<div><p><span><span>Proposing the concept of a brain-gut-skin axis has led some researchers to recognize the relationship among brain activity, gut microbiota, and the skin. </span>Hair follicles<span><span> are skin accessory organs, a previously unnoticed target tissue for classical neurohormones<span>, neurotrophins, and </span></span>neuropeptides<span>. Some studies have shown a relationship between the central nervous system and hair follicles that an imbalance in the gut bacteria can affect hair follicle density. This review summarizes existing evidence from literature and explores clues supporting a connection linking the brain, gut microbiota, and hair follicles. It amalgamates previously proposed partial concepts into a new, unified concept—the “brain-gut microbiota-hair follicle” axis, —which suggests that modulation of the </span></span></span>microbiome<span> via probiotics can have positive effects on hair follicles. This review also explores how preclinical research on hair follicles can propel novel and clinically untapped applications.</span></p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"72 1","pages":"Article 103408"},"PeriodicalIF":4.1,"publicationDate":"2023-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135248858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploration of the mechanism of reinfusion of fresh autologous blood in type 2 diabetic body to induce macrophage polarization and inhibit erythrocyte damage 2型糖尿病体回输新鲜自体血诱导巨噬细胞极化、抑制红细胞损伤的机制探讨
4区 医学
Current Research in Translational Medicine Pub Date : 2023-09-01 DOI: 10.1016/j.retram.2023.103415
She-jun Hu, Jia-ming Xu, Man-di Wu, Ke Yue, Ying-hui Cui, Yu Bai, Lai-wei You, Jian-Rong Guo
{"title":"Exploration of the mechanism of reinfusion of fresh autologous blood in type 2 diabetic body to induce macrophage polarization and inhibit erythrocyte damage","authors":"She-jun Hu, Jia-ming Xu, Man-di Wu, Ke Yue, Ying-hui Cui, Yu Bai, Lai-wei You, Jian-Rong Guo","doi":"10.1016/j.retram.2023.103415","DOIUrl":"https://doi.org/10.1016/j.retram.2023.103415","url":null,"abstract":"Type 2 diabetes (T2D) triggers an inflammatory response that can damage red blood cells. M2 macrophages have inhibitory effects on inflammation and play an important role in tissue damage repair and fibrosis. Autologous blood transfusion has the potential to inhibit red blood cell damage by mediating macrophage polarization. Swiss mice were used to establish a suitable type 2 diabetes model and autologous blood transfusion was performed. The mice were executed, the blood of the mice was collected, and CD14+ monocytes were sorted. The expression levels of phenotypic molecules CD16, CD32 and CD206 in CD14+ monocytes were analyzed by flow cytometry. The proportion of M1 and M2 macrophages were analyzed by flow cytometry. The Q value, P50, 2,3-DPG and Na+-K+-ATPase of red blood cells were detected. The red blood cell osmotic fragility test analyzed the RBC osmotic fragility. Western Blot analysis was used to analyze the expression changes of erythrocyte surface membrane proteins or transporters EPB41, S1P, GLTP and SPPL2A. Autologous blood transfusion induced a significant increase in the number of macrophages. The state and capacity of blood cells improved with autologous blood transfusion. Reinfusion of fresh autologous blood in T2D body made erythrocytes shrank. The expression of erythrocyte-related proteins proved that the erythrocyte injury in the Fresh+T2D group was significantly reduced. The reinfusion of fresh autologous blood into the body of patients with type 2 diabetes can induce macrophage polarization to M2, thereby inhibiting red blood cell damage.","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"117 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135588287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant 伴有相关血液肿瘤的晚期系统性肥大细胞增多症:阿伐普替尼治疗可促进成功桥接异基因造血细胞移植。
IF 4.1 4区 医学
Current Research in Translational Medicine Pub Date : 2023-07-01 DOI: 10.1016/j.retram.2023.103398
P Sriskandarajah , D P McLornan , C Oni , AJ Wilson , C Woodley , M Ciesielska , K Raj , R Dillon , M Ethell , J Chacko , K Orchard , DH Radia
{"title":"Advanced Systemic Mastocytosis with associated haematological neoplasm: Treatment with avapritinib can facilitate successful bridge to allogeneic haematopoietic cell transplant","authors":"P Sriskandarajah ,&nbsp;D P McLornan ,&nbsp;C Oni ,&nbsp;AJ Wilson ,&nbsp;C Woodley ,&nbsp;M Ciesielska ,&nbsp;K Raj ,&nbsp;R Dillon ,&nbsp;M Ethell ,&nbsp;J Chacko ,&nbsp;K Orchard ,&nbsp;DH Radia","doi":"10.1016/j.retram.2023.103398","DOIUrl":"10.1016/j.retram.2023.103398","url":null,"abstract":"<div><p><span>Advanced systemic mastocytosis<span> (AdvSM) is a rare, life-limiting mast cell (MC) neoplasm, with approximately 70% patients having an associated haematological neoplasm (AHN). Avapritinib<span>, a selective tyrosine kinase inhibitor targeting KIT D816V, has shown potent activity </span></span></span>translating clinically into durable responses in the phase 1 EXPLORER (NCT02561988) and phase 2 PATHFINDER (NCT03580655) studies.</p><p>We report three patients with AdvSM-AHN on avapritinib who achieved complete remission (CR) of SM and were successfully bridged to allogeneic haematopoietic cell<span> transplant (allo-HCT). Two cases additionally highlight the risk of clonal evolution<span> within the AHN component and requirement for close monitoring while on targeted therapy.</span></span></p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103398"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9655660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Coexistence of three hematological malignancies in association with a first time documented mutation: “One train can hide another”°, and even more! 三种血液系统恶性肿瘤的共存与首次记录的突变有关:“一列火车可以隐藏另一列”°,甚至更多!
IF 4.1 4区 医学
Current Research in Translational Medicine Pub Date : 2023-07-01 DOI: 10.1016/j.retram.2023.103403
Tamim Alsuliman , Souhila Ikhlef , Nicolas Stocker , Fazia Kaoui , Laure Ricard , Malek Aoudjhane , Mohamad Mohty , Zora Marjanovic
{"title":"Coexistence of three hematological malignancies in association with a first time documented mutation: “One train can hide another”°, and even more!","authors":"Tamim Alsuliman ,&nbsp;Souhila Ikhlef ,&nbsp;Nicolas Stocker ,&nbsp;Fazia Kaoui ,&nbsp;Laure Ricard ,&nbsp;Malek Aoudjhane ,&nbsp;Mohamad Mohty ,&nbsp;Zora Marjanovic","doi":"10.1016/j.retram.2023.103403","DOIUrl":"10.1016/j.retram.2023.103403","url":null,"abstract":"<div><p>Coexisting malignancies is not only an uncommon event but, it can also represent a medical challenge. Its complexity relies on the difficulty of management and the need for personalized and prioritized therapeutic approaches, on the one hand, and in the potential misdiagnosis of recurrence or even a de novo disease, on the other.</p><p>Here, we present a case of a 69-year-old patient, who was initially diagnosed with a chronic myelomonocytic leukemia (CMML), followed by monoclonal gammopathy<span> of uncertain significance (MGUS). Few years later, the patient developed Hodgkin's lymphoma (HL), and a new mutation, previously undocumented in the medical literature, was also detected.</span></p><p><span>As a conclusion, we can say that the decision must be taken with caution and must be based on two major factors: 1- The rapid evolution of malignancies: give priority to treating the most rapid/life-threatening disease. 2- Prioritize the treatment of symptomatic disease and/or that which may most improve patients’ </span>quality of life.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103403"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation 具有独特KRAS突变的新型乳腺植入物相关间变性大细胞淋巴瘤细胞系和PDX模型(BIA-XR1)的建立和表征。
IF 4.1 4区 医学
Current Research in Translational Medicine Pub Date : 2023-07-01 DOI: 10.1016/j.retram.2023.103401
Ioanna Xagoraris , Konstantina Stathopoulou , Roberta D' Aulerio , Minghui He , Anett Ketscher , Kenbugul Jatta , Felix Haglund de Flon , Gisela Barbany , Richard Rosenquist , Lisa S. Westerberg , George Z. Rassidakis
{"title":"Establishment and characterization of a novel breast implant-associated anaplastic large cell lymphoma cell line and PDX model (BIA-XR1) with a unique KRAS mutation","authors":"Ioanna Xagoraris ,&nbsp;Konstantina Stathopoulou ,&nbsp;Roberta D' Aulerio ,&nbsp;Minghui He ,&nbsp;Anett Ketscher ,&nbsp;Kenbugul Jatta ,&nbsp;Felix Haglund de Flon ,&nbsp;Gisela Barbany ,&nbsp;Richard Rosenquist ,&nbsp;Lisa S. Westerberg ,&nbsp;George Z. Rassidakis","doi":"10.1016/j.retram.2023.103401","DOIUrl":"10.1016/j.retram.2023.103401","url":null,"abstract":"<div><p>Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon T-cell lymphoma type with distinct clinical, molecular and genetic features. Establishment of BIA-ALCL cell lines and patient-derived xenograft (PDX) models are essential experimental tools to investigate the molecular pathogenesis of the disease. We characterized a novel BIA-ALCL cell line and PDX model, named BIA-XR1, derived from a patient with textured breast implant who developed lymphoma. Next-generation sequencing revealed a <em>STAT3</em> mutation, commonly detected in BIA-ALCL, and a unique <em>KRAS</em> mutation reported for the first time in this lymphoma type. Both JAK/STAT3 and RAS/MEK/ERK oncogenic pathways were activated in BIA-XR1, which are targetable with clinically available agents.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103401"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9680246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Splenic irradiation prior to allogeneic transplant conditioning in myelofibrosis: A pilot experience 骨髓纤维化异基因移植前脾照射:一项试点经验。
IF 4.1 4区 医学
Current Research in Translational Medicine Pub Date : 2023-07-01 DOI: 10.1016/j.retram.2023.103400
Edoardo Campodonico , Elisabetta Xue , Simona Piemontese , Anna Chiara , Alessandro Bruno , Gianluca Scorpio , Rosamaria Nitti , Daniele Sannipoli , Giorgio Orofino , Paolo Fiore , Maria Chiara Quattrocchi , Elisa Diral , Daniela Clerici , Francesca Farina , Consuelo Corti , Francesca Lunghi , Maria Teresa Lupo-Stanghellini , Nadia Di Muzio , Fabio Ciceri , Raffaella Greco , Jacopo Peccatori
{"title":"Splenic irradiation prior to allogeneic transplant conditioning in myelofibrosis: A pilot experience","authors":"Edoardo Campodonico ,&nbsp;Elisabetta Xue ,&nbsp;Simona Piemontese ,&nbsp;Anna Chiara ,&nbsp;Alessandro Bruno ,&nbsp;Gianluca Scorpio ,&nbsp;Rosamaria Nitti ,&nbsp;Daniele Sannipoli ,&nbsp;Giorgio Orofino ,&nbsp;Paolo Fiore ,&nbsp;Maria Chiara Quattrocchi ,&nbsp;Elisa Diral ,&nbsp;Daniela Clerici ,&nbsp;Francesca Farina ,&nbsp;Consuelo Corti ,&nbsp;Francesca Lunghi ,&nbsp;Maria Teresa Lupo-Stanghellini ,&nbsp;Nadia Di Muzio ,&nbsp;Fabio Ciceri ,&nbsp;Raffaella Greco ,&nbsp;Jacopo Peccatori","doi":"10.1016/j.retram.2023.103400","DOIUrl":"10.1016/j.retram.2023.103400","url":null,"abstract":"<div><h3>Introduction</h3><p>In the era of JAK inhibitors<span><span><span><span>, allogeneic stem cell transplantation (HSCT) remains the only curative </span>treatment for patients with </span>Myelofibrosis (MF). Splenic irradiation (SI) may be used to reduce </span>spleen size and related symptoms.</span></p></div><div><h3>Methods</h3><p><span><span><span><span>We conducted a retrospective analysis on 14 patients with MF who underwent HSCT with SI from any donor source at our center between June 2016 and March 2021. All patients received a conditioning </span>backbone based on </span>treosulfan and </span>fludarabine<span>, with post-transplant cyclophosphamide (PTCy) and </span></span>sirolimus as graft-versus-host disease (GvHD) prophylaxis. Patients received SI with 10 Gy involved-field radiotherapy in five 2-Gy fractions over the course of a week prior to the beginning of conditioning.</p></div><div><h3>Results</h3><p><span>At transplant all patients were transfusion-dependent and had splenomegaly (median bipolar diameter by ultrasound: 20.75 cm). Overall, 12 patients had received </span>ruxolitinib prior to transplant. Re-evaluation of spleen dimensions was available for 13 patients: median splenic bipolar diameter after at least 3 months from transplant decreased by a median of 25%. With a median post-transplant follow-up of 25 months, 6 patients remain in CR with full-donor chimerism, 3 patients died due to NRM. Overall, 4 patients relapsed. At last follow-up, nine patients are currently alive and achieved transfusion-independence.</p></div><div><h3>Conclusions</h3><p>In a small cohort of mostly ruxolitinib pre-treated patients, SI and treosulfan-based conditioning appeared a safe and effective tool to reduce spleen dimensions and ameliorate symptoms. Future prospective studies with adequate sample size are warranted to further investigate the usefulness and safety of this approach in MF.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103400"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9655659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice 癌症相关静脉血栓形成的初级预防:临床实践中的原理和挑战。
IF 4.1 4区 医学
Current Research in Translational Medicine Pub Date : 2023-07-01 DOI: 10.1016/j.retram.2023.103405
Ismail Elalamy , Alain Cohen-Solal , Olivier Hanon , Mariana Mirabel , Patrick Mismetti , Jean-Philippe Spano
{"title":"Primary prevention of cancer-associated venous thrombosis: Rationale and challenges in clinical practice","authors":"Ismail Elalamy ,&nbsp;Alain Cohen-Solal ,&nbsp;Olivier Hanon ,&nbsp;Mariana Mirabel ,&nbsp;Patrick Mismetti ,&nbsp;Jean-Philippe Spano","doi":"10.1016/j.retram.2023.103405","DOIUrl":"10.1016/j.retram.2023.103405","url":null,"abstract":"<div><p>Cancer-associated venous thrombosis (CAT) is a common, multifactor event known to complicate the course of cancer and jeopardize a patient's prognosis. The current guidelines regarding the prevention of CAT are sometimes considered insufficiently precise about specific situations, or are poorly applied. The expected benefits of thromboprophylaxis are balanced by the risk of major bleeding induced by anticoagulation, which implies a need to accurately identify ambulatory patients at high risk of thrombosis or hemorrhage. The Khorana score is commonly used for this, but is limited by the non-reproducibility of predicted performance across cancer types, and by the fact that antitumor treatment and cardiovascular risks are not included. The COMPASS-CAT score, which includes those two aspects, was found to be a more accurate predictor of venous thromboembolism in patients with lung cancer, and to better distinguish between patients at low or high risk of thrombosis. The frailty of patients with cancer is also a major issue, and should be taken into account when thromboprophylaxis is considered. According to current guidelines, CAT prophylaxis should be considered for hospitalized patients, those for whom surgery is scheduled, or those with pancreatic cancers. In ambulatory patients, decisions should be made according to patient, cancer and antitumoral treatment characteristics. Low molecular weight heparin is the gold standard of CAT prophylaxis. Despite increased risks of bleeding or drug-drug interactions in cancer patients, direct oral anticoagulants could be alternate options for high-risk ambulatory patients that should be accompanied by a careful global analysis of benefits, harms, and patient preferences.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 3","pages":"Article 103405"},"PeriodicalIF":4.1,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9851704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信